$PTGX News

Protagonist Therapeutics (NASDAQ:PTGX): A High Growth Momentum Stock Meeting the Mark Minervini Technical Setup

Protagonist Therapeutics Reports Granting of Inducement Awards

Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $151

Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review

Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued

Protagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review Focus - Has The Bull Case Changed?

Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?

Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $145

Why Wall Street’s Wrong for Loving Protagonist Therapeutics Stock

Protagonist Therapeutics (NASDAQ:PTGX) Shows Technical Strength and High Growth Momentum

Protagonist Therapeutics, Inc. (PTGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

Protagonist Therapeutics To Present Four Abstracts On Rusfertide In Polycythemia Vera At 2026 European Hematology Association Congress In Sweden

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026

Analyst Forecasts For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Are Surging Higher

Protagonist Therapeutics, Inc. Surprised Analysts With A Profit, And Analysts Boosted Their EPS Forecasts

Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 141% One Year Surge?

Citizens Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $137

Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $118

Protagonist Therapeutics Q1 EPS $0.05 Beats $(0.42) Estimate, Sales $56.368M Beat $16.273M Estimate